sorafenib has been researched along with tivozanib in 24 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (tivozanib) | Trials (tivozanib) | Recent Studies (post-2010) (tivozanib) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 105 | 23 | 100 |
| Protein | Taxonomy | sorafenib (IC50) | tivozanib (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0709 | |
| Fibroblast growth factor 2 | Homo sapiens (human) | 0.0709 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.0709 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.0023 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.0032 | |
| Ephrin type-B receptor 2 | Homo sapiens (human) | 0.0175 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.0017 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0783 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.07 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 11 (45.83) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, KW; Kim, MS; Kim, Y; Lee, GS; Lee, K; Lee, Y; Song, JY | 1 |
| Chen, JH; Deng, YL; Kania, RS; McTigue, M; Murray, BW; Solowiej, J | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chen, Y; Fan, L; Gong, Y; Guo, S; Kang, F; Pang, X; Peng, L; Zhan, M | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Garnick, MB | 1 |
| Alekseev, BY; Alyasova, A; Berkenblit, A; Bondarenko, I; Cella, D; Eisen, T; Esteves, B; Harza, M; Hutson, TE; Ivanescu, C; Kogan, M; Krivoshik, A; Lesovoy, V; Lipatov, O; Lyulko, O; Motzer, RJ; Nosov, D; Sternberg, CN; Strahs, A; Szczylik, C; Tomczak, P | 1 |
| Balar, AV; Bangalore, S; Kang, SK; Ohmann, EL; Volodarskiy, A | 1 |
| Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S | 1 |
| Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
| Eisen, T; Hutson, TE; Lipatov, O; Molina, AM; Motzer, R; Nosov, D; Sternberg, CN; Tomczak, P | 1 |
| Belsey, J; Eisen, T; Escudier, B; Gibson, D; Morgan, J; Motzer, R; Porta, C | 1 |
| Altavilla, A; Attademo, L; De Giorgi, U; De Lisi, D; Pignata, S; Procopio, G; Santini, D; Verzoni, E | 1 |
| Atkins, MB; Escudier, BJ; Hutson, TE; McDermott, DF; Needle, MN; Pal, SK; Porta, C; Rini, BI; Verzoni, E | 1 |
| Bex, A | 1 |
| Crucitta, S; Danesi, R; Del Re, M; Fogli, S; Gianfilippo, G; Porta, C; Rini, BI; Schmidinger, M | 1 |
| Wright, KM | 1 |
| Atkins, MB; Escudier, BJ; Hutson, TE; McDermott, DF; Needle, MN; Pal, SK; Porta, C; Powers, D; Rini, BI; Verzoni, E | 1 |
| Bex, A; Hofmann, F; Hwang, EC; Lam, TB; Ljungberg, B; Marconi, LS; Yuan, Y | 1 |
| Atkins, MB; Escudier, BJ; Hutson, TE; McDermott, DF; Needle, MN; Pal, SK; Rini, BI; Szarek, M | 1 |
| Amiri-Kordestani, L; Beaver, JA; Bhatnagar, V; Chang, E; Chen, XH; Fiero, MH; Fourie Zirkelbach, J; Goldberg, KB; Ibrahim, A; Kluetz, PG; Pazdur, R; Qiu, J; Ricks, TK; Tang, S; Weinstock, C; Yu, J; Zahalka, E; Zhang, L; Zhao, M | 1 |
| Atkins, MB; Escudier, B; Hutson, TE; Kasturi, V; McDermott, DF; Pal, SK; Porta, C; Rini, B; Verzoni, E; Zengin, ZB | 1 |
| Atkins, MB; Escudier, B; Hutson, TE; Kasturi, V; McDermott, DF; Meza, L; Pal, SK; Porta, C; Rini, B; Verzoni, E | 1 |
8 review(s) available for sorafenib and tivozanib
| Article | Year |
|---|---|
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzimidazoles; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Quinolines; Quinolones; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Vascular Endothelial Growth Factor A | 2016 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
The role of tivozanib in advanced renal cell carcinoma therapy.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasm Metastasis; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2018 |
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group.
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2019 |
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Topics: Angiogenesis Inhibitors; Anilides; Axitinib; Carcinoma, Renal Cell; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib | 2020 |
Targeted therapy for metastatic renal cell carcinoma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Axitinib; Bevacizumab; Bias; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Phenylurea Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2020 |
7 trial(s) available for sorafenib and tivozanib
| Article | Year |
|---|---|
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Health Status; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Odds Ratio; Phenylurea Compounds; Quality of Life; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome | 2013 |
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cross-Over Studies; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Phenylurea Compounds; Quinolines; Sorafenib; Treatment Outcome; Young Adult | 2018 |
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Quinolines; Research Design; Sorafenib; Survival Rate | 2020 |
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Phenylurea Compounds; Quinolines; Retreatment; Sorafenib; Survival Rate | 2020 |
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasm Recurrence, Local; Phenylurea Compounds; Quinolines; Sorafenib | 2021 |
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2022 |
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Phenylurea Compounds; Sorafenib | 2023 |
9 other study(ies) available for sorafenib and tivozanib
| Article | Year |
|---|---|
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
Topics: Drug Evaluation, Preclinical; Models, Molecular; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors.
Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Crystallography, X-Ray; Disease-Free Survival; Human Umbilical Vein Endothelial Cells; Humans; Kidney Neoplasms; Models, Molecular; Molecular Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Design, synthesis and biological evaluation of deuterated Tivozanib for improving pharmacokinetic properties.
Topics: Animals; Area Under Curve; Deuterium; Enzyme Inhibitors; Half-Life; Male; Phenylurea Compounds; Quinolines; Rats; Rats, Sprague-Dawley | 2015 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Quinolines; Sorafenib | 2013 |
Sequencing therapy for advanced renal cancer.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib | 2020 |
Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC.
Topics: Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Humans; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Metastasis; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2020 |
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Drug Approval; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Phenylurea Compounds; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Treatment Outcome | 2022 |